Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Longitudinal Research02:20

Longitudinal Research

12.0K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
12.0K
Longitudinal Studies01:26

Longitudinal Studies

171
Longitudinal studies are also widely used in other medical and social science fields. For instance, in cardiovascular research, they can monitor patients' health over decades to identify risk factors for heart disease, such as high cholesterol or smoking, and evaluate the long-term effectiveness of preventive measures. Similarly, in mental health studies, researchers might follow individuals from adolescence into adulthood to understand the development and progression of conditions like...
171
Actuarial Approach01:20

Actuarial Approach

80
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
80
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

133
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
133
Crossover Experiments01:16

Crossover Experiments

2.9K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
2.9K
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

154
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
154

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Financial Implications of Vascular Surgery Conference Fees.

Annals of vascular surgery·2026
Same author

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

Neuro-oncology advances·2026
Same author

CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas.

Neuro-oncology advances·2026
Same author

Generalized Pairwise Comparisons in Dose Optimization Oncology Trials: Beyond Safety to Multi-outcome Dose Selection.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid Tumors.

Cancer discovery·2026
Same author

Randomized optimal selection design for dose optimization.

Biometrics·2025

Related Experiment Video

Updated: Jul 11, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K

A Bayesian phase II proof-of-concept design for clinical trials with longitudinal endpoints.

Wen Zhang1, Glen Laird2, Josh Chen2

  • 1Bristol Myers Squibb, Madison, New Jersey, USA.

Statistics in Medicine
|November 8, 2023
PubMed
Summary

This study introduces a flexible Bayesian phase II clinical trial design for longitudinal data, improving efficacy endpoint analysis in studies like pain management. The novel approach enhances statistical power and clinical relevance assessment.

Keywords:
Bayesian phase II designlongitudinal endpointpain managementproof-of-concept design

More Related Videos

Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring
06:32

Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring

Published on: July 14, 2023

1.3K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.2K

Related Experiment Videos

Last Updated: Jul 11, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K
Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring
06:32

Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring

Published on: July 14, 2023

1.3K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.2K

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Longitudinal Data Analysis

Background:

  • Traditional phase II clinical trial designs often rely on single scalar endpoints (binary, continuous, survival).
  • Efficacy endpoints in certain trials, such as pain management, are frequently measured longitudinally over time.
  • Existing designs may not optimally capture the nuances of longitudinal efficacy data.

Purpose of the Study:

  • To propose a novel Bayesian phase II clinical trial design tailored for longitudinal efficacy endpoints.
  • To enhance the analysis of time-dependent treatment effects in clinical trials.
  • To provide a flexible framework accommodating single or multiple longitudinal endpoints.

Main Methods:

  • Utilizes a Bayesian hierarchical model to analyze longitudinal measurements, enabling information borrowing across subjects.
  • Employs Bayesian penalized splines for flexible modeling of subject-specific and population trajectories.
  • Incorporates a group sequential approach with Bayesian criteria for interim and final decisions, considering both statistical significance and clinical relevance.

Main Results:

  • The proposed Bayesian design effectively models longitudinal data using flexible trajectory modeling.
  • Area under the curve (AUC) of the trajectory is used to summarize the overall treatment effect over time.
  • Simulation studies demonstrate the design's robustness and favorable operating characteristics.

Conclusions:

  • The proposed Bayesian phase II design offers a flexible and robust approach for clinical trials with longitudinal endpoints.
  • It improves the assessment of treatment efficacy by incorporating statistical significance and clinical relevance.
  • This design is adaptable for various trial complexities, including multiple endpoints.